An observational,cohort study to compare the efficacy of Fingolimod to injectable disease modifying therapies in patients with relapse remitting Multiple Sclerosis

Trial Profile

An observational,cohort study to compare the efficacy of Fingolimod to injectable disease modifying therapies in patients with relapse remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon (Primary) ; Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 Results (n= approx 25000) assessing propensity score matched comparative effectiveness analysis of dimethyl fumarate relative to interferon, glatiramer acetate, or teriflunomide treated RRMS outpatients in the german neurotransdata registry, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 27 Apr 2018 Results (n= approx 25000) assessing effectiveness analysis of dimethyl fumarate relative to fingolimod-treated RRMS outpatients in the german neurotransdata registry, were presented at the 70th annual meeting of the american academy of neurology.
    • 28 Oct 2017 Results (n= approx 25000) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top